PMID- 27980877
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220309
IS  - 2164-2591 (Print)
IS  - 2164-2591 (Electronic)
IS  - 2164-2591 (Linking)
VI  - 5
IP  - 6
DP  - 2016 Dec
TI  - Suprachoroidal Corticosteroid Administration: A Novel Route for Local Treatment 
      of Noninfectious Uveitis.
PG  - 14
LID - 14
AB  - PURPOSE: To evaluate the safety, tolerability, and preliminary efficacy of 
      suprachoroidal injection of triamcinolone acetonide (TA) in patients with 
      noninfectious uveitis. METHODS: In this Phase 1/2 open-label clinical study, a 
      single suprachoroidal injection of 4-mg TA in 100 muL was performed in the study 
      eye of patients with noninfectious intermediate, posterior, or pan-uveitis, and 
      follow-up obtained for 26 weeks. RESULTS: Nine individuals with chronic uveitis 
      were enrolled. There were 38 reported adverse events (AEs); most were mild or 
      moderate in severity. Approximately half the AEs were ocular. The most common AE 
      was reported by four subjects who experienced ocular pain at or near the time of 
      the injection. All systemic AEs were unrelated to study drug. No steroid-related 
      increases in intraocular pressure (IOP) were observed and no subject required 
      IOP-lowering medication. All eight efficacy-evaluable subjects had improvements 
      in visual acuity. Four subjects, who did not need additional therapy, had on 
      average a greater than 2-line improvement in visual acuity through week 26. Three 
      of four had macular edema at baseline, and two of three had at least a 20% 
      reduction in macular edema at week 26. CONCLUSIONS: The safety and preliminary 
      efficacy data support further investigations of suprachoroidally administered TA 
      as a therapeutic option for the treatment of noninfectious uveitis. TRANSLATIONAL 
      RELEVANCE: Targeted suprachoroidal administration of corticosteroid is a 
      potential local route for the treatment of ocular inflammatory disease, which 
      merits further investigation. (www.ClinicalTrials.gov, NCT01789320).
FAU - Goldstein, Debra A
AU  - Goldstein DA
AD  - Department of Ophthalmology, Feinberg School of Medicine, Northwestern 
      University, Chicago, IL, USA.
FAU - Do, Diana
AU  - Do D
AD  - Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, USA.
FAU - Noronha, Glenn
AU  - Noronha G
AD  - Clearside Biomedical, Inc., Alpharetta, GA, USA.
FAU - Kissner, Jennifer M
AU  - Kissner JM
AD  - Clearside Biomedical, Inc., Alpharetta, GA, USA.
FAU - Srivastava, Sunil K
AU  - Srivastava SK
AD  - Cleveland Clinic, Cole Eye Institute, Cleveland, OH, USA.
FAU - Nguyen, Quan D
AU  - Nguyen QD
AD  - Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT01789320
PT  - Journal Article
DEP - 20161214
PL  - United States
TA  - Transl Vis Sci Technol
JT  - Translational vision science & technology
JID - 101595919
PMC - PMC5156441
OTO - NOTNLM
OT  - drug delivery
OT  - suprachoroidal space
OT  - triamcinolone acetonide
OT  - uveitis
EDAT- 2016/12/17 06:00
MHDA- 2016/12/17 06:01
PMCR- 2016/12/14
CRDT- 2016/12/17 06:00
PHST- 2016/03/18 00:00 [received]
PHST- 2016/10/10 00:00 [accepted]
PHST- 2016/12/17 06:00 [entrez]
PHST- 2016/12/17 06:00 [pubmed]
PHST- 2016/12/17 06:01 [medline]
PHST- 2016/12/14 00:00 [pmc-release]
AID - TVST-16-0353 [pii]
AID - 10.1167/tvst.5.6.14 [doi]
PST - epublish
SO  - Transl Vis Sci Technol. 2016 Dec 14;5(6):14. doi: 10.1167/tvst.5.6.14. 
      eCollection 2016 Dec.